RNAi Technology is anticipated to have CAGR of ~10.5% over 2019-2028. The key factor that would aid in the market growth includes the growth in demand for efficient therapeutics for chronic and acute conditions. The surge in the number of applications of the RNAi technology in molecular diagnostics, especially in the cancer disease is expected to help the industry gain lucrative growth. Furthermore, the improvement in the synthetic delivery carriers and chemical modifications are anticipated to contribute to a significant growth, during the forecast period. The surge in the number of infections would propel the industry. However, the increase in the government regulations over the use of such technology may hamper the market growth.
Top Driver: Growth in the applications to boost the industry
RNAi Technology is projected to grow with the widening of the applications of the RNAi technology in the coming years. RNAi technology enabled every gene in the human genome to serve as a druggable target. This is anticipated to create new opportunities for various vendors to develop a comparatively wider range of targeted therapies. Furthermore, this would help attract many drug manufacturers to invest over the development of RNAi-based targeted cancer therapies. There are several early-phase trials, which have reported crucial clinical responses in the case of RNAi therapies and also directed against targets, especially Kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF). Henceforth, the rising adoption of RNAi technology for undruggable targets is anticipated to propel the market growth in near future.
Oncology to Make Crucial Contribution to Growth of Global RNAi Technology Market
Among therapeutics segments of the global RNAi Technology market, oncology segment is attributed to gain highest revenue shares in the forecast period. Owing to the surge in the investment over development of the technology to treat cancer patients would propel the industry. The efficacy of the technology over the cancer disease coupled with the surge in the patient population would contribute the market to grow significantly in the coming years. The recent advancements, mainly the development of small interfering RNA (siRNA) tolerant to nucleases and the advancement, development of non-viral vectors would help overcome this obstacle and would ease the clinical use of RNAi-based therapeutics in the treatment of cancer. Respiratory Disorders segment is anticipated to gain highest CAGR due to the rise in the patient population and hence would fuel the industry in the next few years.
Surge in healthcare expenditure to Benefit North America Market
North America is experiencing highest revenue growth than any other country and is anticipated to boost further in the coming years. This owes to the growth in the healthcare expenditure coupled with the rise in the awareness programs offered by the government to help maintain better quality of life would help the industry grow at a lucrative pace in the forecast period. The increase in investments on the R&D of the products would help the industry grow further in the near future. Asia-Pacific region is anticipated to experience highest CAGR due to the surge in the patient population coupled with the growth in the awareness regarding the severity of the diseases.
Due to outbreak of COVID-19 the RNAi Technology has observed the highest growth rate in the current scenario. The increase in the Research and development over the treatment alternatives for the disease would help the industry have a lucrative growth in the coming years.
Players to Focus on RNAi Technology
The global RNAi Technology market leaders include Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Ionis Pharmaceuticals, Horizon Discovery Group Plc, Quark Pharmaceuticals Inc., RXI Pharmaceuticals, Arbutus Biopharma Corp., Arrowhead Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Dicerna Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, QIAGEN NV, and Thermo Fisher Scientific Inc.
Alnylam Pharmaceuticals: In April 2020, Blackstone announced it had invested up to $2bn in Alnylam Pharmaceuticals, which is a pioneer in the field of RNA interference (RNAi) medicines across a wide range of disease areas. The aim is to allow Alnylam to achieve a sustainable financial profile without the need for further equity financing in the future, as well as support the research and development (R&D) and commercialisation of promising RNAi medicines to at-need patients.
Benitec Biopharma Inc.: In April 2020, Benitec Biopharma Inc. announced the previously announced transaction to redomicile from Australia to the United States has been fully implemented. The redomiciliation was approved by Benitec shareholders at a Scheme Meeting held on March 26, 2020, and confirmed by the Supreme Court of Queensland on March 30, 2020.
Ionis Pharmaceuticals, Inc.: In April 2017, Ionis Pharmaceuticals, Inc. announced a collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China. Ionis granted Ribo a license for the right to commercialize in China two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third pre-specified Generation 2+ antisense drug.
Scope of the Report
Key Reasons to Purchase this Report
Table of Content
Please fill out the form to receive sample pages of the report